Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2020-07-28

FDA Approved: FASLODEX — Supplemental Application (AstraZeneca Pharmaceuticals LP)

View source ↗

Summary

FDA approved a supplemental labeling application for FASLODEX (fulvestrant) from AstraZeneca Pharmaceuticals LP. The update relates to labeling for this breast …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Faslodex (fulvestrant)

Snippet

SUPPL AP for FASLODEX (FULVESTRANT)